<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050661</url>
  </required_header>
  <id_info>
    <org_study_id>JKR-0337</org_study_id>
    <nct_id>NCT00050661</nct_id>
  </id_info>
  <brief_title>To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris</brief_title>
  <official_title>Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody/ Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Facet Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to study disease relapse after NBUVB and how the administration of
      Daclizumab/placebo alters disease relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first part of the study involves NB-UVB light treatment, a well-established treatment to
      treat psoriasis. In the second part, we are testing a drug known as Humanized CD25 Monoclonal
      Antibody (anti-TAC) or placebo to prevent disease relapse. Anti-TAC is an injectable medicine
      that is also designed to treat psoriasis by blocking a part of the immune system that we
      believe contributes to the disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to disease relapse</measure>
    <time_frame>After a course of NB-UVB treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic assessment of disease activity at relapse for measures of epidermal hyperplasia, leukocyte infiltration, and expression of cytokine-induced inflammatory proteins.</measure>
    <time_frame>before and after NB-UVB treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Narrow Band Ultraviolet B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>312nm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-TAC or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab</intervention_name>
    <description>Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.</description>
    <arm_group_label>anti-TAC or placebo</arm_group_label>
    <other_name>anti-TAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB-UVB</intervention_name>
    <description>total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.</description>
    <arm_group_label>Narrow Band Ultraviolet B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female patients with chronic psoriasis vulgaris (disease stable or worsening
             for &gt; 6 months). Patients age 16 - 21 will be considered on a case to case basis.

             For those patients under the age of 18, parental consent will be obtained.

          2. Extensive skin involvement.

          3. Scale, thickness, and erythema in individual psoriasis lesions of at least moderate
             intensity.

          4. Psoriasis treated with emollients only for 2 weeks prior to treatment

          5. Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris
             involving more than 5% of the body surface.

          6. Patients that are appropriate for treatment with UVB.

        Exclusion Criteria:

          1. Positive serology for HIV, Hepatitis B, or Hepatitis C.

          2. Positive β-HCG titer. For women of childbearing potential, unwillingness or inability
             to use a contraceptive device during this study if negative for β-HCG.

          3. Guttate psoriasis, pustular psoriasis, or whole body erythroderma.

          4. Active infection or persistent fever of unknown origin.

          5. Major concurrent illness, which could worsen following treatment with anti-TAC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Krueger, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2002</study_first_submitted>
  <study_first_submitted_qc>December 17, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2002</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>James Krueger, MD, PhD</name_title>
    <organization>Rockefeller University</organization>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Daclizamub</keyword>
  <keyword>anti-TAC</keyword>
  <keyword>dermatology</keyword>
  <keyword>skin</keyword>
  <keyword>lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

